# Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

> **NCT01915589** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Refametinib (BAY86-9766)

## Key facts

- **NCT ID:** NCT01915589
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-16
- **Primary completion:** 2014-10-08
- **Final completion:** 2014-10-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01915589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01915589, "Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01915589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*